<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Haemophilia B</title><meta name="description" content="Haemophilia B , also spelled hemophilia B , is a blood clotting disorder causing easy bruising and bleeding due to an inherited mutation of the gene for factor IX, and resulting in a deficiency of factor IX. It is less common than factor VIII deficiency (haemophilia A).[3] Haemophilia B was first recognized as a distinct disease entity in 1952.[4] It is also known by the eponym Christmas disease ,[1] named after Stephen Christmas, the first patient described with haemophilia B. In addition, the..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="Hemophilia B, Christmas disease, Factor IX deficiency, Factor IX hemophilia"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Haemophilia_B"/><meta property="og:title" content="Haemophilia B"/><meta property="og:description" content="Haemophilia B , also spelled hemophilia B , is a blood clotting disorder causing easy bruising and bleeding due to an inherited mutation of the gene for factor IX, and resulting in a deficiency of factor IX. It is less common than factor VIII deficiency (haemophilia A).[3] Haemophilia B was first recognized as a distinct disease entity in 1952.[4] It is also known by the eponym Christmas disease ,[1] named after Stephen Christmas, the first patient described with haemophilia B. In addition, the..."/><meta property="og:url" content="https://grokipedia.com/page/Haemophilia_B"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Haemophilia B"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:13.636Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Haemophilia B"/><meta name="twitter:description" content="Haemophilia B , also spelled hemophilia B , is a blood clotting disorder causing easy bruising and bleeding due to an inherited mutation of the gene for factor IX, and resulting in a deficiency of factor IX. It is less common than factor VIII deficiency (haemophilia A).[3] Haemophilia B was first recognized as a distinct disease entity in 1952.[4] It is also known by the eponym Christmas disease ,[1] named after Stephen Christmas, the first patient described with haemophilia B. In addition, the..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="482855af3158b46e1f4de6cc3fe0bc23-99fe71e6d094fc98-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=482855af3158b46e1f4de6cc3fe0bc23,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.48038403426329523,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#haemophilia-b" class="transition-opacity hover:opacity-100 opacity-50">Haemophilia B</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#signs-and-symptoms" class="transition-opacity hover:opacity-100 opacity-50">Signs and symptoms</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#complications" class="transition-opacity hover:opacity-100 opacity-50">Complications</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#genetics" class="transition-opacity hover:opacity-100 opacity-50">Genetics</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#x-chromosome" class="transition-opacity hover:opacity-100 opacity-50">X chromosome</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pathophysiology" class="transition-opacity hover:opacity-100 opacity-50">Pathophysiology</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#diagnosis" class="transition-opacity hover:opacity-100 opacity-50">Diagnosis</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#differential-diagnosis" class="transition-opacity hover:opacity-100 opacity-50">Differential diagnosis</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#treatment" class="transition-opacity hover:opacity-100 opacity-50">Treatment</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#dental-considerations" class="transition-opacity hover:opacity-100 opacity-50">Dental considerations</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#research" class="transition-opacity hover:opacity-100 opacity-50">Research</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#monoclonal-antibodies" class="transition-opacity hover:opacity-100 opacity-50">Monoclonal Antibodies</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#tissue-factor-pathway-inhibitor-tfpi-inhibitors" class="transition-opacity hover:opacity-100 opacity-50">Tissue Factor Pathway Inhibitor (TFPI) Inhibitors</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#small-interfering-rna-sirna-therapies" class="transition-opacity hover:opacity-100 opacity-50">Small Interfering RNA (siRNA) Therapies</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#future-directions" class="transition-opacity hover:opacity-100 opacity-50">Future Directions</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#history" class="transition-opacity hover:opacity-100 opacity-50">History</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#society-and-culture" class="transition-opacity hover:opacity-100 opacity-50">Society and culture</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="haemophilia-b" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Haemophilia B<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>





































<!-- -->
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Haemophilia B</strong> , also spelled <strong>hemophilia B</strong> , is a <span class="inline text-[1em] leading-7">blood clotting</span> disorder causing easy bruising and bleeding due to an inherited <span class="inline text-[1em] leading-7">mutation</span> of the gene for <span class="inline text-[1em] leading-7">factor IX</span>, and resulting in a deficiency of factor IX. It is less common than factor VIII deficiency (<span class="inline text-[1em] leading-7">haemophilia A</span>).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Haemophilia B was first recognized as a distinct disease entity in 1952.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_21qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> It is also known by the eponym <em>Christmas disease</em> ,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_61qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> named after Stephen Christmas, the first patient described with haemophilia B. In addition, the first report of its identification was published in the Christmas edition of the <em><span class="inline text-[1em] leading-7">British Medical Journal</span></em>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Most individuals who have Hemophilia B and experience symptoms are men.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_22abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> The prevalence of Hemophilia B in the population is about one in 40,000; Hemophilia B represents about 15% of patients with hemophilia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_42abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> Many female carriers of the disease have no symptoms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_62abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> However, an estimated 10-25% of female carriers have mild symptoms; in rare cases, female carriers may have moderate or severe symptoms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_82abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup></span>
<h2 id="signs-and-symptoms" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Signs and symptoms<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Symptoms include easy bruising, urinary tract bleeding (haematuria), nosebleeds (epistaxis), and bleeding into joints (haemarthrosis).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_23abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h3 id="complications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Complications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Repeated bleeding into joints can lead to chronic joint disease (hemophilic arthropathy), which may cause pain, limited mobility, and require joint replacement in severe cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_24abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_34abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Intracranial hemorrhage is a serious risk, particularly in severe hemophilia B, and is a leading cause of death.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Other complications include deep muscle hematomas, gastrointestinal bleeding, and thrombosis associated with replacement therapy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_74abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h2 id="genetics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Genetics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="x-chromosome" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">X chromosome<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The factor IX gene is located on the <span class="inline text-[1em] leading-7">X chromosome</span> (Xq27.1-q27.2). It is an <span class="inline text-[1em] leading-7">X-linked</span> recessive trait, which explains why males are affected in greater numbers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_65qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_75qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> A change in the F9 gene, which makes blood clotting factor IX (9), causes haemophilia B.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_95qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In 1990, <span class="inline text-[1em] leading-7">George Brownlee</span> and <span class="inline text-[1em] leading-7">Merlin Crossley</span> identified mutations in the promoter region of the F9 gene that disrupt binding sites for transcription factors, such as C/EBP, preventing expression of factor IX in a rare form known as haemophilia B Leyden. In this variant, patients experience episodes of excessive bleeding in childhood but have few bleeding problems after puberty due to androgen-induced activation of the gene.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_66abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Common mutations in the F9 gene include missense mutations (about 65%), followed by splicing and small deletion/insertion mutations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_26qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In about 10-20% of people born with haemophilia B, there is no history of the disorder in the family. This happens when a genetic change in the F9 gene occurs de novo (randomly) in the egg or sperm cell and is passed on at conception. Once haemophilia B appears in a family, the genetic change is then passed on from parents to children following the X-linked recessive pattern.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_27abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<h2 id="pathophysiology" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Pathophysiology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Factor IX deficiency leads to an increased propensity for haemorrhage, which can be spontaneous or in response to mild trauma.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_28abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Factor IX is a vitamin K-dependent serine protease in the intrinsic coagulation pathway. Its deficiency impairs the intrinsic tenase complex, interfering with the coagulation cascade and causing haemorrhage that can occur spontaneously or in response to minor trauma. Activated factor IX (IXa) activates factor X to Xa, which (with factor Va) generates thrombin to convert fibrinogen to fibrin.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_28qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Activated factor IX (IXa), with cofactor factor VIIIa on platelet surfaces, activates factor X. Platelets provide the phospholipid binding site for this complex in the coagulation pathway.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_29abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<h2 id="diagnosis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Diagnosis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The diagnosis of haemophilia B is suspected based on clinical history of bleeding episodes and family history, and confirmed by laboratory tests.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">Activated partial thromboplastin time (aPTT) as a coagulation screening test (prolonged in moderate to severe cases)<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_12aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></li>
<li class="text-[1em]">Clinical bleeding history or assessment tools (e.g., ISTH-Bleeding Assessment Tool)<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_14aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1kaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></li>
<li class="text-[1em]">Coagulation factor IX activity assays to measure deficiency level and determine severity (severe: &lt;1%, moderate: 1-5%, mild: 6-40% of normal)<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_16aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></li>
<li class="text-[1em]">Molecular genetic testing of the F9 gene to identify pathogenic variants<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></li>
</ul>
<h3 id="differential-diagnosis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Differential diagnosis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The differential diagnosis for haemophilia B includes other inherited bleeding disorders such as haemophilia A, factor XI deficiency, von Willebrand disease, fibrinogen disorders, and Bernard-Soulier syndrome.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></span>
<h2 id="treatment" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Treatment<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Treatment for haemophilia B primarily involves replacement therapy with factor IX concentrates, either plasma-derived or recombinant, administered intravenously.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> For severe cases, prophylactic infusions (typically 25-40 IU/kg 1-2 times weekly) are recommended to prevent spontaneous bleeding episodes and joint damage.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> On-demand treatment is used for acute bleeding or mild cases, with doses aimed at achieving 30-100% factor IX activity depending on severity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Non-steroidal anti-inflammatory drugs (NSAIDs) should be avoided as they can increase bleeding risk.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> For surgical procedures, factor IX replacement is combined with antifibrinolytic agents such as tranexamic acid to minimize bleeding.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Extended half-life factor IX products allow for less frequent dosing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Gene therapies include etranacogene dezaparvovec (Hemgenix), approved by the US Food and Drug Administration (FDA) in November 2022 as the first gene therapy for haemophilia B, enabling sustained factor IX production after a single infusion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> Fidanacogene elaparvovec (Beqvez) was approved in April 2024 for adults with moderate to severe haemophilia B but discontinued from production in February 2025.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Fitusiran (Qfitlia), an RNAi therapeutic that reduces antithrombin levels to enhance clotting, was approved for medical use in the United States in March 2025 for haemophilia A or B with or without inhibitors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup></span>
<h3 id="dental-considerations" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Dental considerations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Surgical treatment, including a simple dental extraction, must be planned to minimize the risk of bleeding, excessive bruising, or haematoma formation. Soft vacuum-formed splints can be used to provide local protection following a dental extraction or prolonged post-extraction bleed.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>
<h2 id="research" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Research<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">In July 2022, results of a gene therapy candidate for haemophilia B called FLT180 were announced; it works using an adeno-associated virus (AAV) to restore the clotting factor IX (FIX) protein. Normal levels of the protein were observed with low doses of the therapy, but immunosuppression was necessitated to decrease the risk of vector-related immune responses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">One notable development in this field is the U.S. Food and Drug Administration (FDA)-approved gene therapy Hemgenix (etranacogene dezaparvovec).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> This single-dose therapy utilizes an AAV vector to deliver a modified Factor IX gene, allowing endogenous production of FIX. Clinical trials have demonstrated that Hemgenix reduces the need for regular FIX infusions and lowers annual bleeding rates in individuals with severe Hemophilia B.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A group of products called hemostasis rebalancing agents, that alter the balance of hemostasis, is currently undergoing a study. The alteration of hemostasis would affect individuals with defective hemostasis (which could cause haemophilia B), have a normal hemostatic response.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Non-factor replacement therapies offer an alternative to traditional FIX infusions by targeting different mechanisms of the coagulation cascade to enhance hemostasis and reduce bleeding episodes.</span>
<h3 id="monoclonal-antibodies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Monoclonal Antibodies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]"><strong>Concizumab</strong>: A monoclonal antibody targeting tissue factor pathway inhibitor (TFPI), designed to restore hemostasis by enhancing thrombin production. The FDA approved concizumab (Alhemo) on July 31, 2025, for once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults and children 12 years and older with hemophilia A or B without inhibitors. Phase 3 trials (e.g., explorer8) demonstrated up to an 86% reduction in annualized bleeding rates compared to no prophylaxis, regardless of inhibitor status in earlier studies, though approved indication excludes inhibitors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ejabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup></li>
</ul>
<h3 id="tissue-factor-pathway-inhibitor-tfpi-inhibitors" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Tissue Factor Pathway Inhibitor (TFPI) Inhibitors<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]"><strong>Concizumab</strong>: A monoclonal antibody targeting TFPI, designed to restore hemostasis by enhancing thrombin production. Currently in late-stage clinical trials, Concizumab has demonstrated efficacy in reducing bleeding episodes in individuals with Hemophilia B, regardless of inhibitor status.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ekabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup></li>
</ul>
<h3 id="small-interfering-rna-sirna-therapies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Small Interfering RNA (siRNA) Therapies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]"><strong>Fitusiran</strong>: An siRNA therapy that utilizes small interfering RNA (siRNA) technology to reduce antithrombin levels, thereby increasing thrombin generation and promoting clot formation. The FDA approved fitusiran (Qfitlia) on March 28, 2025, for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years and older with hemophilia A or B, with or without inhibitors. Phase 3 studies (e.g., ATLAS) showed significant reductions in annualized bleeding rates compared to on-demand treatment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qlabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_12labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup></li>
<li class="text-[1em]">siRNA therapies, such as fitusiran, function by silencing specific genes involved in coagulation regulation. These treatments offer once-monthly subcutaneous dosing, providing a more convenient alternative to traditional FIX therapy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_klabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_slabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup></li>
</ul>
<h3 id="future-directions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Future Directions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Ongoing research continues to investigate novel therapeutic approaches, including enhanced gene therapy vectors with prolonged efficacy, combination therapies that optimize clotting function, and further refinements in non-factor treatments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Recent updates include long-term data from June 2025 showing sustained FIX expression and reduced bleeding over 5 years with etranacogene dezaparvovec in severe hemophilia B patients, with no serious adverse events related to the therapy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> Additionally, a second AAV-based gene therapy, fidanacogene elaparvovec (Beqvez), was FDA-approved in October 2024 but production was halted by Pfizer in early 2025 due to manufacturing challenges; ongoing preclinical studies explore alternative vectors and immune mitigation strategies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Additional studies of gene therapy products and approaches are under way in preclinical studies and later-phase clinical trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<h2 id="history" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">History<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Stephen Christmas (12 February 1947 â€“ 20 December 1993) was the first patient described to have Christmas disease (or haemophilia B) in 1952 by a group of British doctors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> Christmas was born to a British family in England. He was the son of film and television actor Eric Christmas. He emigrated to Toronto, Ontario, Canada, with his family, and it was there at the age of two years that hemophilia was diagnosed at the Hospital for Sick Children. The family returned to London in 1952 to visit their relatives, and during the trip Stephen was admitted to hospital. A sample of his blood was sent to the Oxford Haemophilia Centre in Oxford, where Rosemary Biggs and Robert Gwyn Macfarlane discovered that he was not deficient in Factor VIII, which is normally decreased in classic hemophilia, but a different protein, which received the name Christmas factor in his honour (and later Factor IX).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> Stephen was dependent on blood and plasma transfusions, and was infected with HIV in the period during which blood was not routinely screened for this virus. He became an active worker for the Canadian Hemophilia Society and campaigned for transfusion safety ever since getting infected, but developed AIDS and died from it in 1993.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In the 1950s and 1960s, with newfound technology and gradual advances in medicine, pharmaceutical scientists found a way to take the factor IX from fresh frozen plasma (FFP) and give it to those with haemophilia B. Though they found a way to treat the disease, the FFP contained only a small amount of factor IX, requiring large amounts of FFP to treat an actual bleeding episode, which resulted in the person requiring hospitalization. By the mid-1960s scientists found a way to get a larger amount of factor IX from FFP. By the late 1960s, pharmaceutical scientists found methods to separate the factor IX from plasma, which allows for neatly packaged bottles of factor IX concentrates. With the rise of factor IX concentrates it became easier for people to get treatment at home.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup> Although these advances in medicine had a significant positive impact on the treatment of haemophilia, there were many complications that came with it. By the early 1980s, scientists discovered that the medicines they had created were transferring blood-borne viruses, such as hepatitis, and HIV, the virus that causes AIDS. With the rise of these deadly viruses, scientists had to find improved methods for screening the blood products they received from donors. In 1982, scientists made a breakthrough in medicine and were able to clone factor IX gene. With this new development it decreased the risk of the many viruses. Although the new factor was created, it was not available for haemophilia B patients until 1997.</span>
<span class="mb-4 block break-words text-[1em] leading-7">In 2009, an analysis of genetic markers revealed that haemophilia B was the blood disease affecting many European royal families of the United Kingdom, Germany, Russia and Spain: so-called &quot;Royal Disease&quot;.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></span>
<h2 id="society-and-culture" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Society and culture<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Haemophilia B became known as the &quot;Royal Disease&quot; due to its presence in European royal families. Queen Victoria was a carrier of haemophilia B who passed it on to other ruling families from Russia, Spain, and Germany.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> A 2009 genetic analysis of Romanov remains confirmed that the royal disease was haemophilia B, resolving earlier uncertainty about whether it was type A or B.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><em><span class="inline text-[1em] leading-7">MedlinePlus Encyclopedia</span></em> : <a href="https://medlineplus.gov/ency/article/000539.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Hemophilia B</a></span></div></li><li id="2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Konkle, Barbara A.; Nakaya Fletcher, Shelley (1993). <a href="https://www.ncbi.nlm.nih.gov/books/NBK1495/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Hemophilia B&quot;</a>. <em>GeneReviewsÂ®</em>. University of Washington, Seattle. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/20301668" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">20301668</a>.</span></div></li><li id="3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kliegman, Robert (2011). <em>Nelson textbook of pediatrics</em> (19th ed.). Philadelphia: Saunders. pp. 1700â€“1. <span class="inline text-[1em] leading-7">ISBN</span> 978-1-4377-0755-7.</span></div></li><li id="4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20240226073453/https://patient.info/doctor/haemophilia-b-factor-ix-deficiency" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Haemophilia B (Factor IX Deficiency) information | Patient&quot;</a>. <em>Patient</em>. 3 July 2014. Archived from <a href="https://patient.info/doctor/haemophilia-b-factor-ix-deficiency" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> on 2024-02-26. Retrieved 2016-04-21.</span></div></li><li id="5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Biggs, R.; Douglas, A. S.; Macfarlane, R. G.; Dacie, J. V.; Pitney, W. R.; Merskey, C.; O&#x27;Brien, J. R. (27 December 1952). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2022306" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Christmas Disease&quot;</a>. <em>BMJ</em>. <strong>2</strong> (4799): 1378â€“1382. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1136%2Fbmj.2.4799.1378" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1136/bmj.2.4799.1378</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2022306" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2022306</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/12997790" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">12997790</a>.</span></div></li><li id="6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20221122204108/https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;FDA Approves First Gene Therapy to Treat Adults with Hemophilia B&quot;</a>. <em>U.S.<span class="inline text-[1em] leading-7">Food and Drug Administration</span> (FDA)</em>. 22 November 2022. Archived from <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> on November 22, 2022. Retrieved 22 November 2022. <!-- --> This article incorporates text from this source, which is in the <span class="inline text-[1em] leading-7">public domain</span>.</span></div></li><li id="9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://omim.org/entry/306900" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;OMIM Entry - # 306900 - HEMOPHILIA B; HEMB&quot;</a>. <em>omim.org</em>. Retrieved 2016-10-07.</span></div></li><li id="10" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://medlineplus.gov/genetics/condition/hemophilia/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Hemophilia&quot;</a>.</span></div></li><li id="11" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Services, Department of Health &amp; Human. <a href="https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/haemophilia" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Haemophilia&quot;</a>. <em><a href="http://www.betterhealth.vic.gov.au" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">www.betterhealth.vic.gov.au</a></em>. Retrieved 2025-01-09.</span></div></li><li id="https://www.nature.com/articles/343444a0" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/343444a0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/343444a0</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4496316/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4496316/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4496316/</a></span></div></li><li id="12" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><em><a href="https://emedicine.medscape.com/article/779434-overview" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Hemophilia B (Factor IX Deficiency)</a></em> at <span class="inline text-[1em] leading-7">eMedicine</span></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/29921547/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/29921547/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/29921547/</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK560792/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK560792/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK560792/</a></span></div></li><li id="13" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Beck, Norman (2009). &quot;Transfusion-Related Problems&quot;. <em>Diagnostic Hematology</em>. London: Springer. pp. 407â€“423. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1007%2F978-1-84800-295-1_19" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1007/978-1-84800-295-1_19</a>. <span class="inline text-[1em] leading-7">ISBN</span> 978-1-84800-282-1.</span></div></li><li id="https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/beqvez" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/beqvez" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/beqvez</a></span></div></li><li id="https://www.aabb.org/news-resources/news/article/2025/02/25/pfizer-halts-production-of-fda-approved-hemophilia-b-gene-therapy" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.aabb.org/news-resources/news/article/2025/02/25/pfizer-halts-production-of-fda-approved-hemophilia-b-gene-therapy" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.aabb.org/news-resources/news/article/2025/02/25/pfizer-halts-production-of-fda-approved-hemophilia-b-gene-therapy</a></span></div></li><li id="14" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20250328190517/https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-hemophilia-or-b-or-without-factor-inhibitors" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors&quot;</a>. <em>U.S. Food and Drug Administration</em>. 28 March 2025. Archived from <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-hemophilia-or-b-or-without-factor-inhibitors" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> on March 28, 2025. Retrieved 29 March 2025.</span></div></li><li id="15" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.news.sanofi.us/2025-03-28-Qfitlia-approved-as-the-first-therapy-in-the-US-to-treat-hemophilia-A-or-B-with-or-without-inhibitors" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors&quot;</a>. <em>Sanofi</em> (Press release). 28 March 2025. Retrieved 29 March 2025.</span></div></li><li id="16" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Brewer, Andrew; Correa, Maria Elvira (May 2006). <a href="https://www1.wfh.org/publication/files/pdf-1190.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300"><em>Guildelines for Dental Treatment of Patients with Inherited Bleeding Disorders</em></a> (PDF). Treatment of Hemophilia. Vol. 40. World Federation of Hemophilia. p. 9.</span></div></li><li id="18" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedaily.com/releases/2022/07/220720193711.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Novel gene therapy could reduce bleeding risk for haemophilia patients&quot;</a>. <em>ScienceDaily</em> (Press release). University College London. 20 July 2022.</span></div></li><li id="19" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Gallagher, James (20 July 2022). <a href="https://www.bbc.com/news/health-62240061" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Transformational therapy cures haemophilia B&quot;</a>. <em>BBC News</em>.</span></div></li><li id="20" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Mancuso, Maria Elisa; Mahlangu, Johnny N.; Pipe, Steven W. (2021-02-13). &quot;The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing&quot;. <em>Lancet</em>. <strong>397</strong> (10274): 630â€“640. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2FS0140-6736%2820%2932722-7" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/S0140-6736(20)32722-7</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1474-547X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1474-547X</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/33460559" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">33460559</a>.</span></div></li><li id="https://www.prnewswire.com/news-releases/fda-approves-alhemo-as-once-daily-prophylactic-treatment-to-prevent-or-reduce-the-frequency-of-bleeding-episodes-for-adults-and-children-12-years-of-age-and-older-with-hemophilia-a-or-b-hahb-without-inhibitors-302519177.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.prnewswire.com/news-releases/fda-approves-alhemo-as-once-daily-prophylactic-treatment-to-prevent-or-reduce-the-frequency-of-bleeding-episodes-for-adults-and-children-12-years-of-age-and-older-with-hemophilia-a-or-b-hahb-without-inhibitors-302519177.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.prnewswire.com/news-releases/fda-approves-alhemo-as-once-daily-prophylactic-treatment-to-prevent-or-reduce-the-frequency-of-bleeding-episodes-for-adults-and-children-12-years-of-age-and-older-with-hemophilia-a-or-b-hahb-without-inhibitors-302519177.html</a></span></div></li><li id="21" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kaczmarek, Radoslaw; Herzog, Roland W. (2023). &quot;Looking to the future of gene therapy for hemophilia A and B&quot;. <em>Expert Review of Hematology</em>. <strong>16</strong> (11): 807â€“809. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1080%2F17474086.2023.2268279" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1080/17474086.2023.2268279</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1747-4094" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1747-4094</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/37798911" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">37798911</a>.</span></div></li><li id="https://www.nejm.org/doi/abs/10.1056/NEJMoa2414783" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/abs/10.1056/NEJMoa2414783" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/abs/10.1056/NEJMoa2414783</a></span></div></li><li id="22" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Giangrande, Paul L. F. (June 2003). &quot;Six Characters in Search of An Author: The History of the Nomenclature of Coagulation Factors&quot;. <em>British Journal of Haematology</em>. <strong>121</strong> (5): 703â€“712. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1046%2Fj.1365-2141.2003.04333.x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1046/j.1365-2141.2003.04333.x</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/12780784" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">12780784</a>.</span></div></li><li id="https://hekint.org/2020/01/22/from-eponym-to-advocate-the-story-of-stephen-christmas/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://hekint.org/2020/01/22/from-eponym-to-advocate-the-story-of-stephen-christmas/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://hekint.org/2020/01/22/from-eponym-to-advocate-the-story-of-stephen-christmas/</a></span></div></li><li id="https://www.helencowan.co.uk/story-stephen-christmas" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.helencowan.co.uk/story-stephen-christmas" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.helencowan.co.uk/story-stephen-christmas</a></span></div></li><li id="23" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Schramm, Wolfgang (November 2014). &quot;The history of haemophilia â€“ a short review&quot;. <em>Thrombosis Research</em>. <strong>134</strong> : S4 â€“ S9. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.thromres.2013.10.020" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.thromres.2013.10.020</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/24513149" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">24513149</a>.</span></div></li><li id="24" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">&quot;Case Closed: Famous Royals Suffered From Hemophilia&quot;. <em>ScienceAdviser</em>. 18 October 2021. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1126%2Farticle.31560" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1126/article.31560</a>.</span></div></li><li id="25" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Rogaev, Evgeny I.; Grigorenko, Anastasia P.; Faskhutdinova, Gulnaz; Kittler, Ellen L. W.; Moliaka, Yuri K. (6 November 2009). <a href="https://doi.org/10.1126%2Fscience.1180660" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Genotype Analysis Identifies the Cause of the &#x27;Royal Disease&#x27;&quot;</a>. <em>Science</em>. <strong>326</strong> (5954): 817. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/2009Sci...326..817R" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2009Sci...326..817R</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1126%2Fscience.1180660" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1126/science.1180660</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/19815722" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">19815722</a>.</span></div></li></ol></div><div class="text-fg-secondary text-xs [&amp;_*]:mb-2"><hr class="border-border-l1 my-8 rounded-sm border-t"/>
<span class="mb-4 block break-words text-[1em] leading-7">The content is adapted from <a href="https://en.wikipedia.org/wiki/Haemophilia_B" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Wikipedia</a>, licensed under Creative Commons Attribution-ShareAlike 4.0 License.</span></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5" id="_R_" async=""></script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5\"}]\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Haemophilia_B\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Haemophilia_B\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Haemophilia_B\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T3e09,"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"# Haemophilia B\n\n| Attribute          | Details                                                                 |\n|--------------------|-------------------------------------------------------------------------|\n| Other names        | Hemophilia B, Christmas disease                                         |\n| Inheritance        | [X-linked recessive](X-linked_recessive \"X-linked recessive\") manner    |\n| Specialty          | [Haematology](Haematology \"Haematology\")                                |\n| Symptoms           | Easy bruising[1]                                                        |\n| Causes             | Factor IX deficiency[1]                                                 |\n| Diagnostic method  | Bleeding scores, Coagulation factor assays[2]                           |\n| Treatment          | Factor IX concentrate[1]                                                |\n\n**Haemophilia B** , also spelled **hemophilia B** , is a [blood clotting](Coagulation \"Coagulation\") disorder causing easy bruising and bleeding due to an inherited [mutation](Mutation \"Mutation\") of the gene for [factor IX](Factor_IX \"Factor IX\"), and resulting in a deficiency of factor IX. It is less common than factor VIII deficiency ([haemophilia A](Haemophilia_A \"Haemophilia A\")).[3]\n\nHaemophilia B was first recognized as a distinct disease entity in 1952.[4] It is also known by the eponym _Christmas disease_ ,[1] named after Stephen Christmas, the first patient described with haemophilia B. In addition, the first report of its identification was published in the Christmas edition of the _[British Medical Journal](British_Medical_Journal \"British Medical Journal\")_.[4][5]\n\nMost individuals who have Hemophilia B and experience symptoms are men.[6] The prevalence of Hemophilia B in the population is about one in 40,000; Hemophilia B represents about 15% of patients with hemophilia.[6] Many female carriers of the disease have no symptoms.[6] However, an estimated 10-25% of female carriers have mild symptoms; in rare cases, female carriers may have moderate or severe symptoms.[6]\n## Signs and symptoms\n\nSymptoms include easy bruising, urinary tract bleeding (haematuria), nosebleeds (epistaxis), and bleeding into joints (haemarthrosis).[1]\n\n### Complications\n\nRepeated bleeding into joints can lead to chronic joint disease (hemophilic arthropathy), which may cause pain, limited mobility, and require joint replacement in severe cases.[1][2] Intracranial hemorrhage is a serious risk, particularly in severe hemophilia B, and is a leading cause of death.[2] Other complications include deep muscle hematomas, gastrointestinal bleeding, and thrombosis associated with replacement therapy.[1]\n## Genetics\n\n### X chromosome\n\nThe factor IX gene is located on the [X chromosome](X_chromosome \"X chromosome\") (Xq27.1-q27.2). It is an [X-linked](X-linked \"X-linked\") recessive trait, which explains why males are affected in greater numbers.[9][10] A change in the F9 gene, which makes blood clotting factor IX (9), causes haemophilia B.[11]\n\nIn 1990, [George Brownlee](George_Brownlee \"George Brownlee\") and [Merlin Crossley](Merlin_Crossley \"Merlin Crossley\") identified mutations in the promoter region of the F9 gene that disrupt binding sites for transcription factors, such as C/EBP, preventing expression of factor IX in a rare form known as haemophilia B Leyden. In this variant, patients experience episodes of excessive bleeding in childhood but have few bleeding problems after puberty due to androgen-induced activation of the gene.[](https://www.nature.com/articles/343444a0)\n\nCommon mutations in the F9 gene include missense mutations (about 65%), followed by splicing and small deletion/insertion mutations.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4496316/)\n\nIn about 10-20% of people born with haemophilia B, there is no history of the disorder in the family. This happens when a genetic change in the F9 gene occurs de novo (randomly) in the egg or sperm cell and is passed on at conception. Once haemophilia B appears in a family, the genetic change is then passed on from parents to children following the X-linked recessive pattern.[9]\n## Pathophysiology\n\nFactor IX deficiency leads to an increased propensity for haemorrhage, which can be spontaneous or in response to mild trauma.[12]\n\nFactor IX is a vitamin K-dependent serine protease in the intrinsic coagulation pathway. Its deficiency impairs the intrinsic tenase complex, interfering with the coagulation cascade and causing haemorrhage that can occur spontaneously or in response to minor trauma. Activated factor IX (IXa) activates factor X to Xa, which (with factor Va) generates thrombin to convert fibrinogen to fibrin.[12]\n\nActivated factor IX (IXa), with cofactor factor VIIIa on platelet surfaces, activates factor X. Platelets provide the phospholipid binding site for this complex in the coagulation pathway.[12]\n## Diagnosis\n\nThe diagnosis of haemophilia B is suspected based on clinical history of bleeding episodes and family history, and confirmed by laboratory tests.[2]\n\n* Activated partial thromboplastin time (aPTT) as a coagulation screening test (prolonged in moderate to severe cases)[2]\n* Clinical bleeding history or assessment tools (e.g., ISTH-Bleeding Assessment Tool)[2][](https://pubmed.ncbi.nlm.nih.gov/29921547/)\n* Coagulation factor IX activity assays to measure deficiency level and determine severity (severe: \u003c1%, moderate: 1-5%, mild: 6-40% of normal)[2]\n* Molecular genetic testing of the F9 gene to identify pathogenic variants[2]\n\n### Differential diagnosis\n\nThe differential diagnosis for haemophilia B includes other inherited bleeding disorders such as haemophilia A, factor XI deficiency, von Willebrand disease, fibrinogen disorders, and Bernard-Soulier syndrome.[](https://www.ncbi.nlm.nih.gov/books/NBK560792/)\n## Treatment\n\nTreatment for haemophilia B primarily involves replacement therapy with factor IX concentrates, either plasma-derived or recombinant, administered intravenously.[2] For severe cases, prophylactic infusions (typically 25-40 IU/kg 1-2 times weekly) are recommended to prevent spontaneous bleeding episodes and joint damage.[12] On-demand treatment is used for acute bleeding or mild cases, with doses aimed at achieving 30-100% factor IX activity depending on severity.[2][12]\n\nNon-steroidal anti-inflammatory drugs (NSAIDs) should be avoided as they can increase bleeding risk.[4] For surgical procedures, factor IX replacement is combined with antifibrinolytic agents such as tranexamic acid to minimize bleeding.[4][13]\n\nExtended half-life factor IX products allow for less frequent dosing.[2]\n\nGene therapies include etranacogene dezaparvovec (Hemgenix), approved by the US Food and Drug Administration (FDA) in November 2022 as the first gene therapy for haemophilia B, enabling sustained factor IX production after a single infusion.[6] Fidanacogene elaparvovec (Beqvez) was approved in April 2024 for adults with moderate to severe haemophilia B but discontinued from production in February 2025.[](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/beqvez)[](https://www.aabb.org/news-resources/news/article/2025/02/25/pfizer-halts-production-of-fda-approved-hemophilia-b-gene-therapy)\n\nFitusiran (Qfitlia), an RNAi therapeutic that reduces antithrombin levels to enhance clotting, was approved for medical use in the United States in March 2025 for haemophilia A or B with or without inhibitors.[14][15]\n\n### Dental considerations\n\nSurgical treatment, including a simple dental extraction, must be planned to minimize the risk of bleeding, excessive bruising, or haematoma formation. Soft vacuum-formed splints can be used to provide local protection following a dental extraction or prolonged post-extraction bleed.[16]\n## Research\n\nIn July 2022, results of a gene therapy candidate for haemophilia B called FLT180 were announced; it works using an adeno-associated virus (AAV) to restore the clotting factor IX (FIX) protein. Normal levels of the protein were observed with low doses of the therapy, but immunosuppression was necessitated to decrease the risk of vector-related immune responses.[18][19]\n\nOne notable development in this field is the U.S. Food and Drug Administration (FDA)-approved gene therapy Hemgenix (etranacogene dezaparvovec).[6] This single-dose therapy utilizes an AAV vector to deliver a modified Factor IX gene, allowing endogenous production of FIX. Clinical trials have demonstrated that Hemgenix reduces the need for regular FIX infusions and lowers annual bleeding rates in individuals with severe Hemophilia B.[6]\n\nA group of products called hemostasis rebalancing agents, that alter the balance of hemostasis, is currently undergoing a study. The alteration of hemostasis would affect individuals with defective hemostasis (which could cause haemophilia B), have a normal hemostatic response.[20]\n\nNon-factor replacement therapies offer an alternative to traditional FIX infusions by targeting different mechanisms of the coagulation cascade to enhance hemostasis and reduce bleeding episodes. \n\n### Monoclonal Antibodies\n- **Concizumab**: A monoclonal antibody targeting tissue factor pathway inhibitor (TFPI), designed to restore hemostasis by enhancing thrombin production. The FDA approved concizumab (Alhemo) on July 31, 2025, for once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults and children 12 years and older with hemophilia A or B without inhibitors. Phase 3 trials (e.g., explorer8) demonstrated up to an 86% reduction in annualized bleeding rates compared to no prophylaxis, regardless of inhibitor status in earlier studies, though approved indication excludes inhibitors.[](https://www.prnewswire.com/news-releases/fda-approves-alhemo-as-once-daily-prophylactic-treatment-to-prevent-or-reduce-the-frequency-of-bleeding-episodes-for-adults-and-children-12-years-of-age-and-older-with-hemophilia-a-or-b-hahb-without-inhibitors-302519177.html)\n\n### Tissue Factor Pathway Inhibitor (TFPI) Inhibitors\n- **Concizumab**: A monoclonal antibody targeting TFPI, designed to restore hemostasis by enhancing thrombin production. Currently in late-stage clinical trials, Concizumab has demonstrated efficacy in reducing bleeding episodes in individuals with Hemophilia B, regardless of inhibitor status.[20]\n\n### Small Interfering RNA (siRNA) Therapies\n- **Fitusiran**: An siRNA therapy that utilizes small interfering RNA (siRNA) technology to reduce antithrombin levels, thereby increasing thrombin generation and promoting clot formation. The FDA approved fitusiran (Qfitlia) on March 28, 2025, for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years and older with hemophilia A or B, with or without inhibitors. Phase 3 studies (e.g., ATLAS) showed significant reductions in annualized bleeding rates compared to on-demand treatment.[14][15]\n- siRNA therapies, such as fitusiran, function by silencing specific genes involved in coagulation regulation. These treatments offer once-monthly subcutaneous dosing, providing a more convenient alternative to traditional FIX therapy.[14][15]\n\n### Future Directions\nOngoing research continues to investigate novel therapeutic approaches, including enhanced gene therapy vectors with prolonged efficacy, combination therapies that optimize clotting function, and further refinements in non-factor treatments.[20][21] Recent updates include long-term data from June 2025 showing sustained FIX expression and reduced bleeding over 5 years with etranacogene dezaparvovec in severe hemophilia B patients, with no serious adverse events related to the therapy.[](https://www.nejm.org/doi/abs/10.1056/NEJMoa2414783) Additionally, a second AAV-based gene therapy, fidanacogene elaparvovec (Beqvez), was FDA-approved in October 2024 but production was halted by Pfizer in early 2025 due to manufacturing challenges; ongoing preclinical studies explore alternative vectors and immune mitigation strategies.[21][](https://www.aabb.org/news-resources/news/article/2025/02/25/pfizer-halts-production-of-fda-approved-hemophilia-b-gene-therapy)\n\nAdditional studies of gene therapy products and approaches are under way in preclinical studies and later-phase clinical trials.[21]\n## History\n\nStephen Christmas (12 February 1947 â€“ 20 December 1993) was the first patient described to have Christmas disease (or haemophilia B) in 1952 by a group of British doctors.[22] Christmas was born to a British family in England. He was the son of film and television actor Eric Christmas. He emigrated to Toronto, Ontario, Canada, with his family, and it was there at the age of two years that hemophilia was diagnosed at the Hospital for Sick Children. The family returned to London in 1952 to visit their relatives, and during the trip Stephen was admitted to hospital. A sample of his blood was sent to the Oxford Haemophilia Centre in Oxford, where Rosemary Biggs and Robert Gwyn Macfarlane discovered that he was not deficient in Factor VIII, which is normally decreased in classic hemophilia, but a different protein, which received the name Christmas factor in his honour (and later Factor IX).[22][](https://hekint.org/2020/01/22/from-eponym-to-advocate-the-story-of-stephen-christmas/) Stephen was dependent on blood and plasma transfusions, and was infected with HIV in the period during which blood was not routinely screened for this virus. He became an active worker for the Canadian Hemophilia Society and campaigned for transfusion safety ever since getting infected, but developed AIDS and died from it in 1993.[](https://www.helencowan.co.uk/story-stephen-christmas)\n\nIn the 1950s and 1960s, with newfound technology and gradual advances in medicine, pharmaceutical scientists found a way to take the factor IX from fresh frozen plasma (FFP) and give it to those with haemophilia B. Though they found a way to treat the disease, the FFP contained only a small amount of factor IX, requiring large amounts of FFP to treat an actual bleeding episode, which resulted in the person requiring hospitalization. By the mid-1960s scientists found a way to get a larger amount of factor IX from FFP. By the late 1960s, pharmaceutical scientists found methods to separate the factor IX from plasma, which allows for neatly packaged bottles of factor IX concentrates. With the rise of factor IX concentrates it became easier for people to get treatment at home.[23] Although these advances in medicine had a significant positive impact on the treatment of haemophilia, there were many complications that came with it. By the early 1980s, scientists discovered that the medicines they had created were transferring blood-borne viruses, such as hepatitis, and HIV, the virus that causes AIDS. With the rise of these deadly viruses, scientists had to find improved methods for screening the blood products they received from donors. In 1982, scientists made a breakthrough in medicine and were able to clone factor IX gene. With this new development it decreased the risk of the many viruses. Although the new factor was created, it was not available for haemophilia B patients until 1997. \n\nIn 2009, an analysis of genetic markers revealed that haemophilia B was the blood disease affecting many European royal families of the United Kingdom, Germany, Russia and Spain: so-called \"Royal Disease\".[24][25]\n## Society and culture\n\nHaemophilia B became known as the \"Royal Disease\" due to its presence in European royal families. Queen Victoria was a carrier of haemophilia B who passed it on to other ruling families from Russia, Spain, and Germany.[25] A 2009 genetic analysis of Romanov remains confirmed that the royal disease was haemophilia B, resolving earlier uncertainty about whether it was type A or B.[25]"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761887597859,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _[MedlinePlus Encyclopedia](MedlinePlus \\\"MedlinePlus\\\")_ : [Hemophilia B](https://medlineplus.gov/ency/article/000539.htm)\",\"description\":\"1. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _[MedlinePlus Encyclopedia](MedlinePlus \\\"MedlinePlus\\\")_ : [Hemophilia B](https://medlineplus.gov/ency/article/000539.htm)\",\"url\":\"MedlinePlus \\\"MedlinePlus\\\"\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"_**a**_ _**b**_ Konkle, Barbara A.; Nakaya Fletcher, Shelley (1993). [\\\"Hemophilia B\\\"](https://www.ncbi.nlm.nih.gov/books/NBK1495/). _GeneReviewsÂ®_. University of Washington, Seattle. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20301668](https://pubmed.ncbi.nlm.nih.gov/20301668).\",\"description\":\"2. ^ _**a**_ _**b**_ Konkle, Barbara A.; Nakaya Fletcher, Shelley (1993). [\\\"Hemophilia B\\\"](https://www.ncbi.nlm.nih.gov/books/NBK1495/). _GeneReviewsÂ®_. University of Washington, Seattle. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20301668](https://pubmed.ncbi.nlm.nih.gov/20301668).\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK1495/\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"** Kliegman, Robert (2011). _Nelson textbook of pediatrics_ (19th ed.). Philadelphia: Saunders. pp. 1700â€“1\\\\. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-1-4377-0755-7.\",\"description\":\"3. **^** Kliegman, Robert (2011). _Nelson textbook of pediatrics_ (19th ed.). Philadelphia: Saunders. pp. 1700â€“1\\\\. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-1-4377-0755-7.\",\"url\":\"ISBN_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"_**a**_ _**b**_ _**c**_ [\\\"Haemophilia B (Factor IX Deficiency) information | Patient\\\"](https://web.archive.org/web/20240226073453/https://patient.info/doctor/haemophilia-b-factor-ix-deficiency). _Patient_. 3 July 2014. Archived from [the original](https://patient.info/doctor/haemophilia-b-factor-ix-deficiency) on 2024-02-26. Retrieved 2016-04-21.\",\"description\":\"4. ^ _**a**_ _**b**_ _**c**_ [\\\"Haemophilia B (Factor IX Deficiency) information | Patient\\\"](https://web.archive.org/web/20240226073453/https://patient.info/doctor/haemophilia-b-factor-ix-deficiency). _Patient_. 3 July 2014. Archived from [the original](https://patient.info/doctor/haemophilia-b-factor-ix-deficiency) on 2024-02-26. Retrieved 2016-04-21.\",\"url\":\"https://web.archive.org/web/20240226073453/https://patient.info/doctor/haemophilia-b-factor-ix-deficiency\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"_**a**_ _**b**_ Biggs, R.; Douglas, A. S.; Macfarlane, R. G.; Dacie, J. V.; Pitney, W. R.; Merskey, C.; O'Brien, J. R. (27 December 1952). [\\\"Christmas Disease\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2022306). _BMJ_. **2** (4799): 1378â€“1382\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1136/bmj.2.4799.1378](https://doi.org/10.1136%2Fbmj.2.4799.1378). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2022306](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2022306). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12997790](https://pubmed.ncbi.nlm.nih.gov/12997790).\",\"description\":\"5. ^ _**a**_ _**b**_ Biggs, R.; Douglas, A. S.; Macfarlane, R. G.; Dacie, J. V.; Pitney, W. R.; Merskey, C.; O'Brien, J. R. (27 December 1952). [\\\"Christmas Disease\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2022306). _BMJ_. **2** (4799): 1378â€“1382\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1136/bmj.2.4799.1378](https://doi.org/10.1136%2Fbmj.2.4799.1378). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2022306](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2022306). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12997790](https://pubmed.ncbi.nlm.nih.gov/12997790).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2022306\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ [\\\"FDA Approves First Gene Therapy to Treat Adults with Hemophilia B\\\"](https://web.archive.org/web/20221122204108/https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b). _U.S.[Food and Drug Administration](Food_and_Drug_Administration \\\"Food and Drug Administration\\\") (FDA)_. 22 November 2022. Archived from [the original](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b) on November 22, 2022. Retrieved 22 November 2022. ![Public Domain](./_assets_/PD-icon.svg.png) This article incorporates text from this source, which is in the [public domain](Public_domain \\\"Public domain\\\").\",\"description\":\"6. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ [\\\"FDA Approves First Gene Therapy to Treat Adults with Hemophilia B\\\"](https://web.archive.org/web/20221122204108/https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b). _U.S.[Food and Drug Administration](Food_and_Drug_Administration \\\"Food and Drug Administration\\\") (FDA)_. 22 November 2022. Archived from [the original](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b) on November 22, 2022. Retrieved 22 November 2022. ![Public Domain](./_assets_/PD-icon.svg.png) This article incorporates text from this source, which is in the [public domain](Public_domain \\\"Public domain\\\").\",\"url\":\"https://web.archive.org/web/20221122204108/https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"_**a**_ _**b**_ [\\\"Hemophilia A\\\"](https://cdho.org/factsheets/hemophilia-a/). _College of Dental Hygienists of Ontario_.\",\"description\":\"7. ^ _**a**_ _**b**_ [\\\"Hemophilia A\\\"](https://cdho.org/factsheets/hemophilia-a/). _College of Dental Hygienists of Ontario_.\",\"url\":\"https://cdho.org/factsheets/hemophilia-a/\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"_**a**_ _**b**_ Glick, Michael (2015). _Burket's Oral Medicine_ (12th ed.). PMPH USA. pp. 473, 475, 481, 482. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-1-60795-188-9.\",\"description\":\"8. ^ _**a**_ _**b**_ Glick, Michael (2015). _Burket's Oral Medicine_ (12th ed.). PMPH USA. pp. 473, 475, 481, 482. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-1-60795-188-9.\",\"url\":\"ISBN_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"_**a**_ _**b**_ [\\\"OMIM Entry - # 306900 - HEMOPHILIA B; HEMB\\\"](http://omim.org/entry/306900). _omim.org_. Retrieved 2016-10-07.\",\"description\":\"9. ^ _**a**_ _**b**_ [\\\"OMIM Entry - # 306900 - HEMOPHILIA B; HEMB\\\"](http://omim.org/entry/306900). _omim.org_. Retrieved 2016-10-07.\",\"url\":\"http://omim.org/entry/306900\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ [\\\"Hemophilia\\\"](https://medlineplus.gov/genetics/condition/hemophilia/).\",\"description\":\"10. ^ _**a**_ _**b**_ _**c**_ _**d**_ [\\\"Hemophilia\\\"](https://medlineplus.gov/genetics/condition/hemophilia/).\",\"url\":\"https://medlineplus.gov/genetics/condition/hemophilia/\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"_**a**_ _**b**_ Services, Department of Health \u0026 Human. [\\\"Haemophilia\\\"](https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/haemophilia). _www.betterhealth.vic.gov.au_. Retrieved 2025-01-09.\",\"description\":\"11. ^ _**a**_ _**b**_ Services, Department of Health \u0026 Human. [\\\"Haemophilia\\\"](https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/haemophilia). _www.betterhealth.vic.gov.au_. Retrieved 2025-01-09.\",\"url\":\"https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/haemophilia\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"_**a**_ _**b**_ _**c**_ _[Hemophilia B (Factor IX Deficiency)](https://emedicine.medscape.com/article/779434-overview)_ at [eMedicine](EMedicine \\\"EMedicine\\\")\",\"description\":\"12. ^ _**a**_ _**b**_ _**c**_ _[Hemophilia B (Factor IX Deficiency)](https://emedicine.medscape.com/article/779434-overview)_ at [eMedicine](EMedicine \\\"EMedicine\\\")\",\"url\":\"https://emedicine.medscape.com/article/779434-overview\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"_**a**_ _**b**_ Beck, Norman (2009). \\\"Transfusion-Related Problems\\\". _Diagnostic Hematology_. London: Springer. pp. 407â€“423\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/978-1-84800-295-1_19](https://doi.org/10.1007%2F978-1-84800-295-1_19). [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-1-84800-282-1.\",\"description\":\"13. ^ _**a**_ _**b**_ Beck, Norman (2009). \\\"Transfusion-Related Problems\\\". _Diagnostic Hematology_. London: Springer. pp. 407â€“423\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/978-1-84800-295-1_19](https://doi.org/10.1007%2F978-1-84800-295-1_19). [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-1-84800-282-1.\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"** [\\\"FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors\\\"](https://web.archive.org/web/20250328190517/https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-hemophilia-or-b-or-without-factor-inhibitors). _U.S. Food and Drug Administration_. 28 March 2025. Archived from [the original](https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-hemophilia-or-b-or-without-factor-inhibitors) on March 28, 2025. Retrieved 29 March 2025.\",\"description\":\"14. **^** [\\\"FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors\\\"](https://web.archive.org/web/20250328190517/https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-hemophilia-or-b-or-without-factor-inhibitors). _U.S. Food and Drug Administration_. 28 March 2025. Archived from [the original](https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-hemophilia-or-b-or-without-factor-inhibitors) on March 28, 2025. Retrieved 29 March 2025.\",\"url\":\"https://web.archive.org/web/20250328190517/https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-hemophilia-or-b-or-without-factor-inhibitors\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"** [\\\"Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors\\\"](https://www.news.sanofi.us/2025-03-28-Qfitlia-approved-as-the-first-therapy-in-the-US-to-treat-hemophilia-A-or-B-with-or-without-inhibitors). _Sanofi_ (Press release). 28 March 2025. Retrieved 29 March 2025.\",\"description\":\"15. **^** [\\\"Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors\\\"](https://www.news.sanofi.us/2025-03-28-Qfitlia-approved-as-the-first-therapy-in-the-US-to-treat-hemophilia-A-or-B-with-or-without-inhibitors). _Sanofi_ (Press release). 28 March 2025. Retrieved 29 March 2025.\",\"url\":\"https://www.news.sanofi.us/2025-03-28-Qfitlia-approved-as-the-first-therapy-in-the-US-to-treat-hemophilia-A-or-B-with-or-without-inhibitors\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"_**a**_ _**b**_ Brewer, Andrew; Correa, Maria Elvira (May 2006). [_Guildelines for Dental Treatment of Patients with Inherited Bleeding Disorders_](https://www1.wfh.org/publication/files/pdf-1190.pdf) (PDF). Treatment of Hemophilia. Vol. 40\\\\. World Federation of Hemophilia. p. 9.\",\"description\":\"16. ^ _**a**_ _**b**_ Brewer, Andrew; Correa, Maria Elvira (May 2006). [_Guildelines for Dental Treatment of Patients with Inherited Bleeding Disorders_](https://www1.wfh.org/publication/files/pdf-1190.pdf) (PDF). Treatment of Hemophilia. Vol. 40\\\\. World Federation of Hemophilia. p. 9.\",\"url\":\"https://www1.wfh.org/publication/files/pdf-1190.pdf\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"_**a**_ _**b**_ Chowdary, Pratima; Shapiro, Susan; Makris, Mike; Evans, Gillian; Boyce, Sara; Talks, Kate; Dolan, Gerard; Reiss, Ulrike; Phillips, Mark; Riddell, Anne; Peralta, Maria R.; Quaye, Michelle; Patch, David W.; Tuddenham, Edward; Dane, Allison; WatissÃ©e, Marie; Long, Alison; Nathwani, Amit (21 July 2022). [\\\"Phase 1â€“2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B\\\"](https://doi.org/10.1056%2FNEJMoa2119913). _New England Journal of Medicine_. **387** (3): 237â€“247\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJMoa2119913](https://doi.org/10.1056%2FNEJMoa2119913). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [35857660](https://pubmed.ncbi.nlm.nih.gov/35857660).\",\"description\":\"17. ^ _**a**_ _**b**_ Chowdary, Pratima; Shapiro, Susan; Makris, Mike; Evans, Gillian; Boyce, Sara; Talks, Kate; Dolan, Gerard; Reiss, Ulrike; Phillips, Mark; Riddell, Anne; Peralta, Maria R.; Quaye, Michelle; Patch, David W.; Tuddenham, Edward; Dane, Allison; WatissÃ©e, Marie; Long, Alison; Nathwani, Amit (21 July 2022). [\\\"Phase 1â€“2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B\\\"](https://doi.org/10.1056%2FNEJMoa2119913). _New England Journal of Medicine_. **387** (3): 237â€“247\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJMoa2119913](https://doi.org/10.1056%2FNEJMoa2119913). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [35857660](https://pubmed.ncbi.nlm.nih.gov/35857660).\",\"url\":\"https://doi.org/10.1056%2FNEJMoa2119913\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"** [\\\"Novel gene therapy could reduce bleeding risk for haemophilia patients\\\"](https://www.sciencedaily.com/releases/2022/07/220720193711.htm). _ScienceDaily_ (Press release). University College London. 20 July 2022.\",\"description\":\"18. **^** [\\\"Novel gene therapy could reduce bleeding risk for haemophilia patients\\\"](https://www.sciencedaily.com/releases/2022/07/220720193711.htm). _ScienceDaily_ (Press release). University College London. 20 July 2022.\",\"url\":\"https://www.sciencedaily.com/releases/2022/07/220720193711.htm\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"** Gallagher, James (20 July 2022). [\\\"Transformational therapy cures haemophilia B\\\"](https://www.bbc.com/news/health-62240061). _BBC News_.\",\"description\":\"19. **^** Gallagher, James (20 July 2022). [\\\"Transformational therapy cures haemophilia B\\\"](https://www.bbc.com/news/health-62240061). _BBC News_.\",\"url\":\"https://www.bbc.com/news/health-62240061\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"** Mancuso, Maria Elisa; Mahlangu, Johnny N.; Pipe, Steven W. (2021-02-13). \\\"The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing\\\". _Lancet_. **397** (10274): 630â€“640\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/S0140-6736(20)32722-7](https://doi.org/10.1016%2FS0140-6736%2820%2932722-7). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1474-547X](https://search.worldcat.org/issn/1474-547X). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [33460559](https://pubmed.ncbi.nlm.nih.gov/33460559).\",\"description\":\"20. **^** Mancuso, Maria Elisa; Mahlangu, Johnny N.; Pipe, Steven W. (2021-02-13). \\\"The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing\\\". _Lancet_. **397** (10274): 630â€“640\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/S0140-6736(20)32722-7](https://doi.org/10.1016%2FS0140-6736%2820%2932722-7). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1474-547X](https://search.worldcat.org/issn/1474-547X). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [33460559](https://pubmed.ncbi.nlm.nih.gov/33460559).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"** Kaczmarek, Radoslaw; Herzog, Roland W. (2023). \\\"Looking to the future of gene therapy for hemophilia A and B\\\". _Expert Review of Hematology_. **16** (11): 807â€“809\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1080/17474086.2023.2268279](https://doi.org/10.1080%2F17474086.2023.2268279). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1747-4094](https://search.worldcat.org/issn/1747-4094). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [37798911](https://pubmed.ncbi.nlm.nih.gov/37798911).\",\"description\":\"21. **^** Kaczmarek, Radoslaw; Herzog, Roland W. (2023). \\\"Looking to the future of gene therapy for hemophilia A and B\\\". _Expert Review of Hematology_. **16** (11): 807â€“809\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1080/17474086.2023.2268279](https://doi.org/10.1080%2F17474086.2023.2268279). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1747-4094](https://search.worldcat.org/issn/1747-4094). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [37798911](https://pubmed.ncbi.nlm.nih.gov/37798911).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"_**a**_ _**b**_ _**c**_ Giangrande, Paul L. F. (June 2003). \\\"Six Characters in Search of An Author: The History of the Nomenclature of Coagulation Factors\\\". _British Journal of Haematology_. **121** (5): 703â€“712\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1046/j.1365-2141.2003.04333.x](https://doi.org/10.1046%2Fj.1365-2141.2003.04333.x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12780784](https://pubmed.ncbi.nlm.nih.gov/12780784).\",\"description\":\"22. ^ _**a**_ _**b**_ _**c**_ Giangrande, Paul L. F. (June 2003). \\\"Six Characters in Search of An Author: The History of the Nomenclature of Coagulation Factors\\\". _British Journal of Haematology_. **121** (5): 703â€“712\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1046/j.1365-2141.2003.04333.x](https://doi.org/10.1046%2Fj.1365-2141.2003.04333.x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12780784](https://pubmed.ncbi.nlm.nih.gov/12780784).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"** Schramm, Wolfgang (November 2014). \\\"The history of haemophilia â€“ a short review\\\". _Thrombosis Research_. **134** : S4 â€“ S9. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.thromres.2013.10.020](https://doi.org/10.1016%2Fj.thromres.2013.10.020). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24513149](https://pubmed.ncbi.nlm.nih.gov/24513149).\",\"description\":\"23. **^** Schramm, Wolfgang (November 2014). \\\"The history of haemophilia â€“ a short review\\\". _Thrombosis Research_. **134** : S4 â€“ S9. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.thromres.2013.10.020](https://doi.org/10.1016%2Fj.thromres.2013.10.020). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24513149](https://pubmed.ncbi.nlm.nih.gov/24513149).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"** \\\"Case Closed: Famous Royals Suffered From Hemophilia\\\". _ScienceAdviser_. 18 October 2021. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/article.31560](https://doi.org/10.1126%2Farticle.31560).\",\"description\":\"24. **^** \\\"Case Closed: Famous Royals Suffered From Hemophilia\\\". _ScienceAdviser_. 18 October 2021. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/article.31560](https://doi.org/10.1126%2Farticle.31560).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"** Rogaev, Evgeny I.; Grigorenko, Anastasia P.; Faskhutdinova, Gulnaz; Kittler, Ellen L. W.; Moliaka, Yuri K. (6 November 2009). [\\\"Genotype Analysis Identifies the Cause of the 'Royal Disease'\\\"](https://doi.org/10.1126%2Fscience.1180660). _Science_. **326** (5954): 817. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2009Sci...326..817R](https://ui.adsabs.harvard.edu/abs/2009Sci...326..817R). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/science.1180660](https://doi.org/10.1126%2Fscience.1180660). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19815722](https://pubmed.ncbi.nlm.nih.gov/19815722).\",\"description\":\"25. **^** Rogaev, Evgeny I.; Grigorenko, Anastasia P.; Faskhutdinova, Gulnaz; Kittler, Ellen L. W.; Moliaka, Yuri K. (6 November 2009). [\\\"Genotype Analysis Identifies the Cause of the 'Royal Disease'\\\"](https://doi.org/10.1126%2Fscience.1180660). _Science_. **326** (5954): 817. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2009Sci...326..817R](https://ui.adsabs.harvard.edu/abs/2009Sci...326..817R). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/science.1180660](https://doi.org/10.1126%2Fscience.1180660). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19815722](https://pubmed.ncbi.nlm.nih.gov/19815722).\",\"url\":\"https://doi.org/10.1126%2Fscience.1180660\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"** Park R (December 2013). [\\\"Attempts to treat patients with hemophilia, the \\\"royal disease\\\"\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894377). _Blood Res_. **48** (4): 235â€“6\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.5045/br.2013.48.4.235](https://doi.org/10.5045%2Fbr.2013.48.4.235). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3894377](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894377). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24466543](https://pubmed.ncbi.nlm.nih.gov/24466543).\",\"description\":\"26. **^** Park R (December 2013). [\\\"Attempts to treat patients with hemophilia, the \\\"royal disease\\\"\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894377). _Blood Res_. **48** (4): 235â€“6\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.5045/br.2013.48.4.235](https://doi.org/10.5045%2Fbr.2013.48.4.235). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3894377](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894377). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24466543](https://pubmed.ncbi.nlm.nih.gov/24466543).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894377\",\"favicon\":\"\"}],\"images\":[],\"fixedIssues\":[{\"criticality\":\"Critical\",\"issueType\":\"Internal Contradiction\",\"problematicText\":\"\\\"Patients with bleeding disorders show a higher incidence of periodontal disease as well as dental caries\\\" and later \\\"Children with severe haemophilia have significant lower prevalence of dental caries\\\"\",\"explanation\":\"The section claims a higher incidence of dental caries but later states a lower prevalence in children with severe hemophilia, creating mutually inconsistent claims within the same subsection.\",\"fixedText\":\"Remove the contradictory claims about dental caries incidence to resolve the inconsistency.\",\"evidenceSource\":\"[1]\"},{\"criticality\":\"Critical\",\"issueType\":\"Quantitative/Units Error\",\"problematicText\":\"\\\"Average 29.1 bleeding events per year are serious enough to require factor replacement in F VIII-deficient patients which 9% involved oral structures.\\\"\",\"explanation\":\"This statistic specifically applies to FVIII-deficient patients (hemophilia A), not hemophilia B (FIX deficiency). Hemophilia B generally involves fewer bleeding events, making this figure inaccurate for the context and potentially misleading on disease severity.\",\"fixedText\":\"Remove the sentence, as no equivalent verified statistic exists for hemophilia B.\",\"evidenceSource\":\"[2]; https://www.ncbi.nlm.nih.gov/books/NBK1495/\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"The paragraph citing [7]: \\\"Patients with bleeding disorders show a higher incidence... TMJ may be observed.[7]\\\"\",\"explanation\":\"Citation [7] is specifically for hemophilia A, not B, and does not support claims tailored to hemophilia B. Applying it here misrepresents the source's scope.\",\"fixedText\":\"Remove the citation and the unsupported dental-specific content, as it duplicates material better suited to the \\\"Dental considerations\\\" subsection under Treatment.\",\"evidenceSource\":\"References list: [7] [\\\"Hemophilia A\\\"](https://cdho.org/factsheets/hemophilia-a/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"The entire \\\"Complications\\\" subsection focuses exclusively on oral and dental issues.\",\"explanation\":\"The subsection presents only minor, procedure-related oral complications as representative of all complications, omitting major, life-altering ones like chronic joint disease and intracranial hemorrhage, which are central to hemophilia B's impact.\",\"fixedText\":\"Rewrite the subsection to cover primary complications such as hemophilic arthropathy and intracranial bleeding, minimizing or removing dental focus to align with the section's scope and avoid duplication with other article sections.\",\"evidenceSource\":\"[1]; [2]\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No mention of key complications like chronic joint disease or intracranial hemorrhage.\",\"explanation\":\"The section lacks essential details on the most significant long-term effects and risks of hemophilia B, leaving a knowledge gap on disease progression and morbidity.\",\"fixedText\":\"Add verified descriptions of major complications, citing reliable sources.\",\"evidenceSource\":\"[1]; https://medlineplus.gov/ency/article/000539.htm ; [2]; https://www.ncbi.nlm.nih.gov/books/NBK1495/\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"In 1990, [George Brownlee](George_Brownlee \\\"George Brownlee\\\") and [Merlin Crossley](Merlin_Crossley \\\"Merlin Crossley\\\") showed that two sets of [genetic mutations](Genetic_mutations \\\"Genetic mutations\\\") were preventing two key [proteins](Proteins \\\"Proteins\\\") from attaching to the [DNA](DNA \\\"DNA\\\") of people with a rare and unusual form of haemophilia B â€“ _haemophilia B Leyden_ â€“ where patients experience episodes of excessive bleeding in childhood but have few bleeding problems after puberty.[10] This lack of protein attachment to the DNA was thereby turning off the gene that produces [clotting factor IX](Factor_IX \\\"Factor IX\\\"), which prevents excessive bleeding.[10]\\\"\",\"explanation\":\"The cited source [10] (MedlinePlus on hemophilia) mentions hemophilia B Leyden briefly as an unusual form but does not describe the 1990 discovery by Brownlee and Crossley, the specific mechanism of mutations preventing protein attachment to DNA, or the two sets of mutations and two key proteins. This misattributes detailed scientific findings not supported by the reference, potentially misleading on historical and mechanistic accuracy.\",\"fixedText\":\"Rephrase to accurately describe the mechanism based on the original paper, citing the proper source, and remove or correct unsupported details like \\\"two sets\\\" and \\\"two key proteins\\\" which oversimplify multiple identified mutations affecting promoter binding sites, primarily C/EBP.\",\"evidenceSource\":\"[](https://www.nature.com/articles/343444a0) (Crossley and Brownlee, Nature, 1990)\"},{\"criticality\":\"Critical\",\"issueType\":\"Quantitative/Units Error\",\"problematicText\":\"\\\"In about one third of people born with haemophilia, there is no history of the disorder in the family.\\\"\",\"explanation\":\"The figure \\\"one third\\\" (â‰ˆ33%) applies primarily to hemophilia A; for hemophilia B specifically, de novo/sporadic cases are estimated at 10-20% based on genetic databases and studies, not one third. This quantitative inaccuracy misrepresents the inheritance pattern for hemophilia B.\",\"fixedText\":\"Correct to \\\"approximately 10-20%\\\" or \\\"about one-fifth\\\" for hemophilia B, citing reliable sources.\",\"evidenceSource\":\"[9] (OMIM #306900); [](https://pmc.ncbi.nlm.nih.gov/articles/PMC4496316/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"This happens when a genetic change in the F8 or F9 gene occurs randomly during reproduction and is passed on at conception. ... following the usual pattern for haemophilia.[11]\\\"\",\"explanation\":\"The cited source [11] (Better Health Channel) provides general information on hemophilia but does not mention de novo mutations, the proportion of cases, or specifics about F8/F9 genes occurring randomly during reproduction. It lacks support for these claims, especially in the context of hemophilia B (F9 only).\",\"fixedText\":\"Remove the citation [11] as it does not support; replace with appropriate source for de novo mutations in F9 gene.\",\"evidenceSource\":\"[](https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/haemophilia)\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"\\\"This happens when a genetic change in the F8 or F9 gene occurs randomly during reproduction and is passed on at conception.\\\"\",\"explanation\":\"This section is on genetics of hemophilia B, caused by F9 mutations; mentioning F8 (for hemophilia A) introduces irrelevant information from hemophilia A, misstating the scope for this article/section and potentially confusing readers about the specific genetic cause.\",\"fixedText\":\"Specify only F9 gene for hemophilia B to maintain section focus; avoid referencing F8.\",\"evidenceSource\":\"[9] (OMIM, specific to F9 for HEMB)\"},{\"criticality\":\"Missing Information\",\"issueType\":\"Missing Information\",\"problematicText\":\"None\",\"explanation\":\"The section lacks detail on common types of F9 mutations (e.g., missense ~65%, inversions, deletions) which are critical for understanding genetic heterogeneity in hemophilia B, as noted in genetic databases. This gap affects completeness of genetic overview without duplicating other sections like Pathophysiology.\",\"fixedText\":\"Add brief summary of mutation types with citation.\",\"evidenceSource\":\"[9]; [](https://pmc.ncbi.nlm.nih.gov/articles/PMC4496316/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"\\\"Factor IX becomes active eventually in coagulation by cofactor factor VIII (specifically IXa).\\\"\",\"explanation\":\"This incorrectly states that factor VIII activates factor IX. In reality, factor IX is activated to IXa independently (by factor XIa or the factor VIIa-tissue factor complex), and activated factor IX (IXa) then uses factor VIIIa as a cofactor to activate factor X. This misrepresents the sequence in the coagulation cascade, potentially leading to misunderstanding of the intrinsic pathway.\",\"fixedText\":\"Rewrite to clarify that activated factor IX (IXa) forms a complex with factor VIIIa to activate factor X: \\\"Activated factor IX (IXa), with cofactor factor VIIIa on platelet surfaces, activates factor X.\\\"\",\"evidenceSource\":\"[12]\"},{\"criticality\":\"Critical\",\"issueType\":\"Internal Contradiction\",\"problematicText\":\"\\\"thereby causing spontaneous haemorrhage when there is trauma.\\\"\",\"explanation\":\"The phrase combines \\\"spontaneous haemorrhage\\\" (bleeding without provocation) with \\\"when there is trauma\\\" (provoked bleeding), creating a logical inconsistency. In haemophilia B, bleeding can occur spontaneously or after minor trauma due to impaired coagulation.\",\"fixedText\":\"Revise to: \\\"causing haemorrhage, which can occur spontaneously or in response to minor trauma.\\\"\",\"evidenceSource\":\"[12]\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"\\\"Factor IX when activated activates factor X which helps fibrinogen to fibrin conversion.\\\"\",\"explanation\":\"While activated factor IX (IXa) activates factor X, factor X itself does not directly convert fibrinogen to fibrin; activated factor X (Xa) converts prothrombin to thrombin, and thrombin converts fibrinogen to fibrin. This skips key steps in the cascade, inaccurately simplifying the mechanism.\",\"fixedText\":\"Correct to specify the chain: \\\"Activated factor IX (IXa) activates factor X to Xa, which (with factor Va) generates thrombin to convert fibrinogen to fibrin.\\\"\",\"evidenceSource\":\"[12]\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific text; overall section lacks detail on pathway.\",\"explanation\":\"The section omits that factor IX is part of the intrinsic coagulation pathway and a vitamin K-dependent zymogen, which is essential for understanding its role and deficiency effects. This creates a knowledge gap in explaining how deficiency disrupts thrombin generation and clot stability.\",\"fixedText\":\"Add: \\\"Factor IX is a vitamin K-dependent serine protease in the intrinsic coagulation pathway. Its deficiency impairs the intrinsic tenase complex, reducing thrombin and fibrin formation.\\\"\",\"evidenceSource\":\"[12]\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"* Bleeding scores\",\"explanation\":\"The cited source [2] (GeneReviews) discusses a detailed history of bleeding episodes but does not mention \\\"bleeding scores\\\" or formalized tools like ISTH-BAT for diagnosis.\",\"fixedText\":\"Replace \\\"Bleeding scores\\\" with \\\"Clinical bleeding history\\\" citing [2], or add \\\"Bleeding assessment tools (e.g., ISTH-BAT)\\\" with a new citation to a supporting source such as https://pubmed.ncbi.nlm.nih.gov/29921547/.\",\"evidenceSource\":\"[2] https://www.ncbi.nlm.nih.gov/books/NBK1495/\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"The differential diagnosis for this inherited condition is the following: [haemophilia A](Haemophilia_A \\\"Haemophilia A\\\"), [factor XI](Factor_XI \\\"Factor XI\\\") deficiency, [von Willebrand disease](Von_Willebrand_disease \\\"Von Willebrand disease\\\"), [fibrinogen](Fibrinogen \\\"Fibrinogen\\\") disorders and [Bernardâ€“Soulier syndrome](Bernard%E2%80%93Soulier_syndrome \\\"Bernardâ€“Soulier syndrome\\\")[10]\",\"explanation\":\"The cited source [10] (MedlinePlus on Hemophilia) distinguishes hemophilia A and B but does not list factor XI deficiency, von Willebrand disease, fibrinogen disorders, or Bernard-Soulier syndrome as differential diagnoses.\",\"fixedText\":\"Remove [10] and replace with a supporting citation, such as StatPearls https://www.ncbi.nlm.nih.gov/books/NBK560792/, which lists these as differentials for bleeding disorders including hemophilia B.\",\"evidenceSource\":\"[10] https://medlineplus.gov/genetics/condition/hemophilia/\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific mention of key diagnostic components.\",\"explanation\":\"The section omits essential details for accurate diagnosis, such as the specific coagulation screening test (activated partial thromboplastin time, aPTT) and molecular genetic testing to identify F9 gene variants, which are standard per authoritative sources and necessary to distinguish severity and confirm etiology.\",\"fixedText\":\"Add specifications: Coagulation screening includes prolonged aPTT; definitive diagnosis via factor IX activity assay and/or F9 genetic testing, citing [2].\",\"evidenceSource\":\"[2] https://www.ncbi.nlm.nih.gov/books/NBK1495/\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"Treatment is given intermittently, when there is significant bleeding.\",\"explanation\":\"Standard treatment for severe haemophilia B includes prophylactic factor IX replacement to prevent bleeding episodes, not just on-demand treatment for significant bleeding. Omitting prophylaxis misrepresents current guidelines from authoritative sources like WFH and CDC, potentially leading to incomplete understanding of management.\",\"fixedText\":\"Add description of prophylactic treatment as the standard for severe cases, with on-demand for mild or as needed.\",\"evidenceSource\":\"[](https://www1.wfh.org/publications/files/pdf-1863.pdf)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"It includes intravenous infusion of factor IX and/or blood transfusions.\",\"explanation\":\"Blood transfusions are not a standard current treatment for haemophilia B; factor IX concentrates (recombinant or plasma-derived) are preferred to avoid risks like volume overload and infections. Historical use of plasma products has been replaced by safer concentrates. This outdated claim could mislead on best practices.\",\"fixedText\":\"Remove \\\"and/or blood transfusions\\\"; specify factor IX concentrates.\",\"evidenceSource\":\"[](https://www.ncbi.nlm.nih.gov/books/NBK1495/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[No specific text; overall section on advanced therapies]\",\"explanation\":\"The section mentions two gene therapies but omits recent developments, including the 2024 FDA approval of fidanacogene elaparvovec (Beqvez) for moderate to severe haemophilia B, discontinued in 2025. Also, extended half-life factor IX products are standard now. Missing these gaps leaves the treatment landscape incomplete as of 2025.\",\"fixedText\":\"Add brief mention of additional approved therapies, noting discontinuation where applicable, and extended half-life products.\",\"evidenceSource\":\"[](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/beqvez)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"One notable development in this field is the U.S. Food and Drug Administration (FDA)-approved gene therapy Hemgenix (etranacogene dezaparvovec).[5] This single-dose therapy... Clinical trials have demonstrated that Hemgenix reduces the need for regular FIX infusions and lowers annual bleeding rates in individuals with severe Hemophilia B.[7]\\\"\",\"explanation\":\"Ref [5] is a 1952 paper on the initial description of haemophilia B (Christmas disease) and does not mention Hemgenix or gene therapy. Ref [7] is a dental hygiene factsheet on hemophilia A and does not discuss Hemgenix clinical trials.\",\"fixedText\":\"Change citations to [6] for both the approval and clinical trial details, as ref [6] is the FDA press release on Hemgenix approval and outcomes.\",\"evidenceSource\":\"[6]\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"In July 2022 results of a gene therapy candidate for haemophilia B called FLT180 were announced...[17][18][19]\\\"\",\"explanation\":\"Ref [17] describes a phase 1-2 trial of AAVS3 gene therapy (fidanacogene elaparvovec) for hemophilia B, not FLT180, which is a separate AAV therapy developed by Freeline Therapeutics.\",\"fixedText\":\"Remove [17] from the citation, retaining [18][19] which cover the FLT180 announcement.\",\"evidenceSource\":\"[18][19] or [](https://www.theguardian.com/science/2022/jul/21/gene-therapy-trial-markedly-cuts-bleeding-risk-in-haemophilia-b-patients)\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"\\\"1. Monoclonal Antibodies * Fitusiran : An investigational therapy that utilizes small interfering RNA (siRNA) technology to reduce antithrombin levels...\\\"\",\"explanation\":\"Fitusiran is an siRNA-based therapy, not a monoclonal antibody. Placing it under \\\"Monoclonal Antibodies\\\" is a misclassification of its mechanism.\",\"fixedText\":\"Relocate the description of fitusiran to the \\\"Small Interfering RNA (siRNA) Therapies\\\" subsection and remove the duplication there.\",\"evidenceSource\":\"[14] or [](https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-hemophilia-or-b-or-without-factor-inhibitors)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"Fitusiran : An investigational therapy... Early clinical studies suggest that fitusiran can significantly reduce bleeding events...[8] Early clinical studies...[9]\\\"\",\"explanation\":\"Ref [8] is a textbook on oral medicine with no mention of fitusiran. Ref [9] is an OMIM entry on hemophilia B genetics, not on fitusiran trials.\",\"fixedText\":\"Replace citations with [14][15], which are FDA and Sanofi sources on fitusiran (Qfitlia) approval and efficacy data.\",\"evidenceSource\":\"[14][15]\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"Fitusiran : An investigational therapy... Early clinical studies suggest...\\\"\",\"explanation\":\"The description presents fitusiran as investigational with early studies, but it was FDA-approved on March 28, 2025, as Qfitlia for routine prophylaxis in hemophilia A or B (with or without inhibitors) for patients 12 years and older, based on phase 3 data showing reduced bleeding rates.\",\"fixedText\":\"Update to reflect approval status as of March 2025, including brand name Qfitlia and phase 3 efficacy.\",\"evidenceSource\":\"[14][15]\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"Concizumab : A monoclonal antibody targeting TFPI... Currently in late-stage clinical trials, Concizumab has demonstrated efficacy...[13]\\\"\",\"explanation\":\"Ref [13] is a chapter on transfusion-related problems in hematology and does not discuss concizumab or its trials.\",\"fixedText\":\"Replace [13] with a new citation to an authoritative source on concizumab approval and efficacy, such as the FDA press release.\",\"evidenceSource\":\"[](https://www.fda.gov/news-events/press-announcements/fda-approves-alhemo-once-daily-prophylactic-treatment-prevent-or-reduce-frequency-bleeding-episodes)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"Concizumab : A monoclonal antibody... Currently in late-stage clinical trials, Concizumab has demonstrated efficacy in reducing bleeding episodes in individuals with Hemophilia B, regardless of inhibitor status.[13]\\\"\",\"explanation\":\"The text describes concizumab as in late-stage trials, but it was FDA-approved on July 31, 2025, as Alhemo (concizumab-mtci) for prophylaxis in hemophilia A or B without inhibitors for patients 12 years and older, with phase 3 data showing up to 86% reduction in annualized bleeding rates.\",\"fixedText\":\"Update to reflect approval status as of July 2025, including brand name Alhemo, indication limitations (without inhibitors), and phase 3 efficacy data.\",\"evidenceSource\":\"[](https://www.prnewswire.com/news-releases/fda-approves-alhemo-as-once-daily-prophylactic-treatment-to-prevent-or-reduce-the-frequency-of-bleeding-episodes-for-adults-and-children-12-years-of-age-and-older-with-hemophilia-a-or-b-hahb-without-inhibitors-302519177.html)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"3. Small Interfering RNA (siRNA) Therapies * siRNA therapies, such as fitusiran... These treatments offer the potential for once-monthly or less frequent dosing...[16]\\\"\",\"explanation\":\"Ref [16] is guidelines for dental treatment of bleeding disorders and does not discuss siRNA therapies or fitusiran dosing.\",\"fixedText\":\"Replace [16] with [14][15], which cover fitusiran dosing (subcutaneous monthly).\",\"evidenceSource\":\"[14][15]\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"Future Directions Ongoing research continues...[17]\\\"\",\"explanation\":\"Ref [17] is a specific trial report on AAVS3, not a general overview of future directions in gene therapy.\",\"fixedText\":\"Remove [17] and ensure future directions are supported by [20] or [21].\",\"evidenceSource\":\"[20][21]\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific text; overall section lacks updates on recent developments.\",\"explanation\":\"The section omits key 2024-2025 developments, including FDA approval of a second gene therapy (fidanacogene elaparvovec/Beqvez in October 2024, but production halted by Pfizer in early 2025 due to manufacturing issues), long-term data (e.g., 5+ years sustained FIX expression with etranacogene dezaparvovec as of June 2025), and approvals of non-factor therapies like fitusiran and concizumab, which shift from research to clinical use but inform ongoing studies.\",\"fixedText\":\"Add subsections or paragraphs on recent gene therapy updates, including Beqvez status and long-term efficacy data, with appropriate citations to maintain research focus on ongoing/preclinical aspects.\",\"evidenceSource\":\"[14][15] or [](https://www.nejm.org/doi/abs/10.1056/NEJMoa2414783) for long-term data; [](https://www.aabb.org/news-resources/news/article/2025/02/25/pfizer-halts-production-of-fda-approved-hemophilia-b-gene-therapy) for Beqvez halting\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Haemophilia B became known as \\\"Royal Disease\\\" due to its presence in European families. Queen Victoria was a carrier of haemophilia B who later passed these onto other ruling families from Russia, Spain and Germany.[26]\",\"explanation\":\"The cited source [26] discusses hemophilia A treatments and inhibitors, not specifically confirming haemophilia B as the royal disease. Genetic analyses confirm it was haemophilia B (factor IX deficiency), not A.\",\"fixedText\":\"Replace citation [26] with [25] to correctly source the claim that Queen Victoria carried haemophilia B, the royal disease.\",\"evidenceSource\":\"[25] Rogaev et al. (2009) in Science, which analyzed DNA from Romanov remains and identified a mutation in the F9 gene for factor IX, confirming haemophilia B.\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[No specific text; entire section]\",\"explanation\":\"The section lacks mention of the historical debate and genetic confirmation in 2009 that resolved whether the royal disease was haemophilia A or B, confirming it as B. This is a key knowledge gap for accuracy in a cultural/historical context.\",\"fixedText\":\"Add a sentence noting the 2009 DNA confirmation that it was haemophilia B, citing [25].\",\"evidenceSource\":\"[25] and [24]\"}],\"slug\":\"Haemophilia_B\",\"title\":\"Haemophilia B\",\"content\":\"$1f\",\"description\":\"Haemophilia B\\n\\n| Attribute | Details |\\n|--------------------|-------------------------------------------------------------------------|\\n| Other names | Hemophilia B, Christmas disease |\\n| Inheritance...\",\"metadata\":{\"categories\":[\"Hemophilia B\",\"Christmas disease\",\"Factor IX deficiency\",\"Factor IX hemophilia\"],\"lastModified\":\"1761553636\",\"contentLength\":\"15881\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"60765\",\"recentViews\":\"60765\",\"dailyAvgViews\":2025.5,\"qualityScore\":1,\"lastViewed\":\"1761887597\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761887597857,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Haemophilia_B\"],\"queryHash\":\"[\\\"page\\\",\\\"Haemophilia_B\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Haemophilia B\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Haemophilia B , also spelled hemophilia B , is a blood clotting disorder causing easy bruising and bleeding due to an inherited mutation of the gene for factor IX, and resulting in a deficiency of factor IX. It is less common than factor VIII deficiency (haemophilia A).[3] Haemophilia B was first recognized as a distinct disease entity in 1952.[4] It is also known by the eponym Christmas disease ,[1] named after Stephen Christmas, the first patient described with haemophilia B. In addition, the...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"Hemophilia B, Christmas disease, Factor IX deficiency, Factor IX hemophilia\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Haemophilia_B\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Haemophilia B\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Haemophilia B , also spelled hemophilia B , is a blood clotting disorder causing easy bruising and bleeding due to an inherited mutation of the gene for factor IX, and resulting in a deficiency of factor IX. It is less common than factor VIII deficiency (haemophilia A).[3] Haemophilia B was first recognized as a distinct disease entity in 1952.[4] It is also known by the eponym Christmas disease ,[1] named after Stephen Christmas, the first patient described with haemophilia B. In addition, the...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Haemophilia_B\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Haemophilia B\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:13.636Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Haemophilia B\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Haemophilia B , also spelled hemophilia B , is a blood clotting disorder causing easy bruising and bleeding due to an inherited mutation of the gene for factor IX, and resulting in a deficiency of factor IX. It is less common than factor VIII deficiency (haemophilia A).[3] Haemophilia B was first recognized as a distinct disease entity in 1952.[4] It is also known by the eponym Christmas disease ,[1] named after Stephen Christmas, the first patient described with haemophilia B. In addition, the...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="YTFlN2Q4Y2YtNDcwMi00ZTQ4LWE0OTMtNzk2ZTI2YjA2NWY5">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Haemophilia_B\"}]}]\n"])</script></body></html>